Home

Quanterix Corporation - Common Stock (QTRX)

7.2400
+0.0400 (0.56%)

Quanterix Corp is a biotechnology company that specializes in developing and commercializing ultra-sensitive digital immunoassay technology aimed at advancing precision health and diagnostics

By harnessing its innovative platform, Quanterix enables the detection of biomarkers at extremely low levels, facilitating early disease detection, monitoring therapeutic responses, and ultimately enhancing patient care. Their solutions are utilized across various fields, including neurology, oncology, and infectious diseases, driving progress in research and clinical applications to improve health outcomes.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close7.200
Open7.090
Bid6.880
Ask7.640
Day's Range6.960 - 7.450
52 Week Range6.300 - 27.37
Volume1,044,652
Market Cap275.58M
PE Ratio (TTM)-7.240
EPS (TTM)-1.0
Dividend & YieldN/A (N/A)
1 Month Average Volume821,602

News & Press Releases

Quanterix Releases Financial Results for the Fourth Quarter of 2024
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024.
By Quanterix Corporation · Via Business Wire · March 17, 2025
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call
Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent Lake has previously issued a public presentation detailing its opposition to the Company’s proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA), and has also nominated three highly qualified, independent candidates for election to the Company’s Board of Directors (the “Board”).
By Kent Lake PR LLC · Via Business Wire · March 17, 2025
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results
MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024.
By Akoya Biosciences, Inc. · Via GlobeNewswire · March 17, 2025
Earnings Scheduled For March 17, 2025benzinga.com
Via Benzinga · March 17, 2025
Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, March 17, 2025, at 4:30 p.m. E.T., to discuss its fourth quarter and full year 2024 financial results.
By Quanterix Corporation · Via Business Wire · March 13, 2025
Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix’s Proposed Merger with Akoya Biosciences
Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued a presentation to Quanterix shareholders in connection to Kent Lake’s opposition to the Company’s proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA).
By Kent Lake PR LLC · Via Business Wire · March 11, 2025
Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
Kent Lake PR LLC (“Kent Lake”), a holder of 6.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), announced today it has nominated three highly qualified, independent candidates for election to the Company’s Board of Directors (the “Board”) at the 2025 Annual Meeting of Shareholders (the “Annual Meeting”).
By Kent Lake PR LLC · Via Business Wire · March 3, 2025
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed acquisition of Akoya Biosciences, which will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. Quanterix issued the following statement:
By Quanterix Corporation · Via Business Wire · March 3, 2025
Bragar Eagel & Squire, P.C. Is Investigating Quanterix, e.l.f. Beauty, and Silvaco and Encourages Investors to Contact the Firm
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Quanterix Corporation (NASDAQ:QTRX), e.l.f. Beauty, Inc. (NYSE: ELF), and Silvaco Group, Inc. (NASDAQ: SVCO). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · February 24, 2025
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company’s Proposed Merger with Akoya Biosciences
Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today highlighted its opposition to the Company’s proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA). Kent Lake has also issued an open letter to all Quanterix shareholders outlining how the Merger significantly undervalues the Company and its intention to take all necessary steps to vote against the deal.
By Kent Lake PR LLC · Via Business Wire · February 18, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IVAC, AVTE, QTRX on Behalf of Shareholders
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · February 17, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 14, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 11, 2025
Quanterix Investor News: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 5, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Feb. 01, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 1, 2025
Bragar Eagel & Squire, P.C. Is Investigating Quanterix and TransMedics and Encourages Investors to Contact the Firm
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Quanterix Corporation (NASDAQ:QTRX) and TransMedics Group, Inc. (NASDAQ:TMDX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · January 28, 2025
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LGTY, AZPN, RDW, QTRX on Behalf of Shareholders
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · January 28, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 25, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCRN, NARI, VTS, QTRX on Behalf of Shareholders
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · January 24, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NARI, QTRX, CTV on Behalf of Shareholders
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · January 23, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 22, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Jan. 19, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 19, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 15, 2025
Quanterix Provides Update on Financial Performance
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced selected preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.
By Quanterix Corporation · Via Business Wire · January 14, 2025
Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Jan. 12, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 12, 2025